CG Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
CGON$72.64-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| Assets | 2023 | 2022 |
| Current assets: | ||
| Cash and cash equivalents | $8,266 | $88,143 |
| Marketable securities | 179,408 | 55,338 |
| Prepaid expenses and other current assets | 6,358 | 3,424 |
| Other receivables | 92 | 303 |
| Total current assets | 194,124 | 147,208 |
| Property and equipment, net | 69 | 86 |
| Operating lease right-of-use assets | 422 | 420 |
| Other assets | 19 | 33 |
| Deferred offering costs | 4,667 | — |
| Total assets | $199,301 | $147,747 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $3,242 | $985 |
| Success fee liability, current portion | 352 | — |
| Long-term debt, current portion | — | 8,966 |
| Operating lease liabilities, current portion | 217 | 189 |
| Accrued expenses and other current liabilities | 10,443 | 5,289 |
| Total current liabilities | 14,254 | 15,429 |
| Long-term debt | — | 6,532 |
| Success fee liability, net of current portion | 13 | 352 |
| Operating lease liabilities, net of current portion | 244 | 257 |
| Total liabilities | 14,511 | 22,570 |
| Commitments and contingencies (Note 5) | ||
| Redeemable convertible preferred stock: | ||
| Series A-1 redeemable convertible preferred stock, $0.0001 par value per share; 5,075,000 shares authorized, issued and outstanding as of December 31, 2023 and 2022; liquidation value of $3,570 as of December 31, 2023 and 2022 | 3,570 | 3,570 |
| Series B redeemable convertible preferred stock, $0.0001 par value per share; 11,973,000 shares authorized, issued and outstanding as of December 31, 2023 and 2022; liquidation value of $10,000 as of December 31, 2023 and 2022 | 10,000 | 10,000 |
| Series C redeemable convertible preferred stock, $0.0001 par value per share; 73,598,283 shares authorized, issued and outstanding as of December 31, 2023 and 2022; liquidation value of $22,000 as of December 31, 2023 and 2022 | 22,000 | 22,000 |
| Series D redeemable convertible preferred stock, $0.0001 par value per share; 53,271,754 shares authorized, issued and outstanding as of December 31, 2023 and 2022; liquidation value of $47,300 as of December 31, 2023 and 2022 | 47,300 | 47,300 |
| Series E redeemable convertible preferred stock, $0.0001 par value per share; 112,422,700 shares authorized, issued and outstanding as of December 31, 2023 and 2022; liquidation value of $120,000 as of December 31, 2023 and 2022 | 120,000 | 120,000 |
| Series F redeemable convertible preferred stock, $0.0001 par value per share; 81,587,937 and zero shares issued and outstanding as of December 31, 2023 and 2022, respectively; liquidation value of $105,020 and zero as of December 31, 2023 and 2022, respectively | 105,020 | — |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.001 par value per share; 493,530,000 and 393,500,000 shares authorized as of December 31, 2023 and 2022, respectively; 5,222,283 and 3,842,694 shares issued and outstanding at December 31, 2023 and 2022, respectively | — | — |
| Additional paid-in capital | 6,842 | 3,642 |
| Accumulated deficit | (129,942) | (81,335) |
| Total stockholders' deficit | (123,100) | (77,693) |
| Total liabilities, convertible preferred stock and stockholders' deficit | $199,301 | $147,747 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.